Cardiol TherapeuticsCRDL -1.42%34 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates CRDL with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 193798.26% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Cardiol Therapeutics is 0.00%.
The historical rank and industry rank for Cardiol Therapeutics's Dividend Yield % or its related term are showing as below:
CRDL's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.03 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cardiol Therapeutics Dividend Yield % Related Terms
Cardiol Therapeutics Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's Dividend Yield % falls into.
Cardiol Therapeutics (CRDL) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is Cardiol Therapeutics' Dividend Yield % too high?
Cardiol Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Cardiol Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #999999 out of 516 companies for Dividend Yield %. This places Cardiol Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (CRDL) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Cardiol Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Cardiol Therapeutics (CRDL), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score
Get the complete analysis for CRDL
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDL has been successfully added to your 
